- Home
- NMRA vs MTLS Comparison
NMRA vs MTLS Comparison
Compare NMRA & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRA | MTLS |
|---|---|---|
| Founded | 2019 | 1990 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | Computer Software: Prepackaged Software |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 302.0M | 431.6M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NMRA | MTLS |
|---|---|---|
| Price | $0.45 | $8.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | $6.14 | ★ $8.80 |
| AVG Volume (30 Days) | ★ 2.0M | 219.0K |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.97 |
| Revenue Next Year | N/A | $5.95 |
| P/E Ratio | ★ N/A | $61.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $4.78 |
| 52 Week High | $3.65 | $8.82 |
Technical Indicators
Market Signals| Indicator | NMRA | MTLS |
|---|---|---|
| Relative Strength Index (RSI) | 20.43 | 59.81 |
| Support Level | N/A | $6.37 |
| Resistance Level | $1.72 | $8.82 |
| Average True Range (ATR) | 0.06 | 0.26 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 0.55 | 49.04 |
Price Performance
Historical ComparisonAbout NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About MTLS Materialise NV
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.